Ambry Genetics®
A Konica Minolta Company

Get the Complete Picture



Get more complete information to guide ovarian cancer management

TUMORNEXT-*HRD*

GERMLINE TESTING

Identify patients with hereditary ovarian cancer to:

- Determine if they are at increased risk for other cancers
- Guide treatment recommendations, such as PARP inhibitor therapy for *BRCA1* or *BRCA2* carriers
- Identify family members with a significantly increased risk for cancer to guide early detection and prevention

TUMOR TESTING

Identify patients with somatic mutations in *BRCA1, BRCA2* and other genes to:

- Learn if there are variants in the tumor that may cause homologous recombination deficiency (HRD)
- Guide targeted treatment such as with PARP inhibitors[1,2]

WHAT CAN TUMORNEXT-*HRD* DO FOR YOUR PATIENTS?

- Identify genetic variation that may lead to HRD in your patient's ovarian tumor
- Determine if your patient may benefit from PARP inhibitor therapy[1,2,5-13]
- Find patients with hereditary cancer to guide risk counseling and medical management for your patient and their family members

Ambry Genetics®
A Konica Minolta Company

All patients diagnosed with ovarian cancer may benefit from TumorNext-*HRD*

GUIDE TREATMENT BASED ON *BRCA1/2* STATUS:

- Alterations in *BRCA1* and *BRCA2* may predict sensitivity to DNA-damaging drugs, such as platinum therapies and PARP inhibitors[5-7]
- Newly Diagnosed Ovarian Cancer: Maintenance therapy with a PARP inhibitor may be an appropriate treatment for women with a *BRCA1/2* mutation[8]
- Recurrent Platinum Sensitive Ovarian Cancer: PARP inhibitor therapy may be beneficial for *BRCA1/2* carriers[9-13]

NCCN® and SGO recommend germline genetic testing for all patients with epithelial ovarian cancer, fallopian tube, and peritoneal cancer[3,4]

TEST DETAILS

ANALYSIS INCLUDES:

1. Paired tumor/germline analysis of *BRCA1* and *BRCA2* and 9 additional genes in the homologous recombination repair pathway (*ATM, BARD1, BRIP1, CHEK2, MRE11A, NBN, RAD51C, RAD51D*)
2. *BRCA1* and *RAD51C* methylation analysis

ALSO AVAILABLE:

TUMORNEXT-*HRD* PLUS OVANEXT Includes germline analysis of 14 additional genes associated with hereditary ovarian cancer

Turnaround Time

21-28 days (once both samples are received)

Order Requirements

1. Both tumor and normal sample are required to begin testing.
2. Pathology report for relevant tumor REQUIRED

Visit ambrygen.com/specimen-requirements for complete details.

ORDERING PROCESS

1. Complete Tumor Test Requisition Form and submit with blood sample and relevant pathology report
2. Ambry will contact the Pathology department to request the tumor specimen
3. Testing will begin when BOTH blood and tumor samples are received

Please note that the time to receive the tumor specimen depends on individual pathology departments and may delay testing. Follow-up may be needed.

References

1. Hennessy BTJ, *et al.* JCO. 2010 Aug 1;28(22):3570-6
2. Pennington KP *et al.* Clin Cancer Res 2014 Feb 1;20(3):764-75
3. NCCN Clinical Practice Guidelines in Oncology®. Genetic/Familial High-Risk Assessment: Breast and Ovarian. V1.2017
4. SGO Clinical Practice Statement: Genetic Testing for Ovarian Cancer. October 2014
5. Banerjee S & Kaye S. Curr Oncol Rep. 2011 Dec;13(6):442-9
6. Burgess M & Puhalla S. Front Oncol. 2014 Feb 27;4:19
7. Yamamoto KN *et al.* PLoS One. 2014 Aug 26;9(8):e105724
8. Moore *et al.* NEJM 2018 Oct 21 (Epub ahead of print)
9. Ledermann, *et al.* Lancet Oncol. 2014;15(8):852-861
10. Pujade-Lauraine, *et al.* Lancet Oncol. 2017;18:1274-1284
11. Mirza, *et al.* N Engl J Med. 2016;375:2154-2164
12. Coleman RL, *et al.* Lancet. 2017 Oct 28;390(10106):1949-1961
13. Swisher, *et al.* Lancet Oncology 2017 18: 75-87

15 Argonaut, Aliso Viejo, CA 92656 USA Toll Free +1 866 262 7943 Fax +1 949 900 5501 ambrygen.com